Branched chain amino acid composition for supplying energy to skeletal muscle and application of branched chain amino acid composition

Abstract

The invention discloses a branched-chain amino acid composition capable of supplying energy to skeletal muscles and application of the branched-chain amino acid composition, and belongs to the field of preparation of amino acid compositions.The branched-chain amino acid composition capable of supplying energy to the skeletal muscles comprises a component A and a component B; the component B is a dissolving solution of the component A; the component A is prepared from the following components: a stearic acid modified magnesium citrate-lysine hydrochloride compound and betaine-branched chain amino acid eutectic porous particles; the adding amount of the stearic acid modified magnesium citrate-lysine hydrochloride compound accounts for 12-15% of the mass of the betaine-branched chain amino acid eutectic porous particle; and the component B comprises the following components: water, mannitol and an amphiphilic surfactant. The problems that at present, along with increase of the dissolution rate of the branched-chain amino acid composition, the hydrophilic performance, the moisture absorption performance and the like of the branched-chain amino acid composition are remarkably improved, the storage difficulty of the branched-chain amino acid composition is increased, and the service life of the unsealed branched-chain amino acid composition is shortened are solved.

Description

Technical Field

[0001] The invention belongs to the field of preparation of amino acid compositions and relates to a branched-chain amino acid composition for supplying energy to skeletal muscle and application thereof. Background Art

[0002] Branched-chain amino acids (BCAAs) are a collective term for leucine, isoleucine, and valine. BCAAs are the primary amino acids used to fuel skeletal muscle energy, accounting for approximately 60% of the total amino acid energy supply. Even at rest, BCAA oxidation contributes 14% of the energy required for skeletal muscle. BCAAs should be taken within 30-60 minutes before and after training to promote muscle regeneration and synthesis. The recommended dosage is 5-10 grams per serving.

[0003] Leucine, isoleucine, and valine have low solubility in water. Therefore, various types of fast-dissolving branched-chain amino acid compositions have been obtained through surfactant treatment, etc., which significantly improves the dissolution rate of the branched-chain amino acid compositions in water, making the dissolved branched-chain amino acids more conducive to absorption. However, as the dissolution rate of the branched-chain amino acid compositions increases, their hydrophilicity and hygroscopicity properties also increase significantly, which requires strict requirements for the sealing of the branched-chain amino acid composition packaging, increasing the difficulty of packaging. Moreover, for products with large-volume packaging, the shelf life after opening is short because the branched-chain amino acid compositions easily absorb moisture and deteriorate after opening. Summary of the Invention

[0004] The purpose of the present invention is to provide a branched-chain amino acid composition for skeletal muscle energy supply and its application, which solves the current problem that as the dissolution rate of the branched-chain amino acid composition increases, its hydrophilicity, hygroscopicity and other properties will also be significantly improved, which increases the difficulty of preserving the branched-chain amino acid composition and reduces the shelf life of the branched-chain amino acid composition after opening.

[0005] The technical solution adopted in the present invention is as follows: A branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; component B is a solution of component A; The component A comprises the following components: a stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched chain amino acid eutectic porous particles; the amount of the stearic acid-modified magnesium citrate-lysine hydrochloride complex added accounts for 12-15% of the mass of the betaine-branched chain amino acid eutectic porous particles; The component B comprises the following components: water, mannitol, and an amphiphilic surfactant.

[0006] The present application first prepares betaine-branched-chain amino acid eutectic porous particles to improve the water solubility of branched-chain amino acids and ensure the basic fast-dissolving performance of branched-chain amino acids; secondly, on this basis, a stearic acid-modified magnesium citrate-lysine hydrochloride complex is added, and the stearic acid-modified magnesium citrate-lysine hydrochloride complex is filled in the pores of the betaine-branched-chain amino acid eutectic porous particles, and the porous particles are hydrophobically modified, thereby reducing the hydrophilicity and hygroscopicity of the porous particles during storage; in order to balance the two properties of fast solubility in the solvent but hydrophobicity and moisture resistance under storage conditions, the present invention is configured with component B, which is mainly composed of water and added with mannitol and an amphiphilic surfactant; After the stearic acid-modified magnesium citrate-lysine hydrochloride complex is surrounded by component B, under the action of the amphiphilic surfactant, the interfacial tension between the stearic acid-modified magnesium citrate-lysine hydrochloride complex and the aqueous phase is reduced, the penetration resistance of the aqueous phase is reduced, and the wettability of the stearic acid-modified magnesium citrate-lysine hydrochloride complex is increased. As the magnesium citrate-lysine hydrochloride complex fully contacts the aqueous phase, under the bridge action of the surfactant and accompanied by the hypertonicity of the mannitol aqueous solution, a locally enriched ion solution is formed in the aqueous phase. The formation of the ion solution enhances the permeability of water and increases the osmotic pressure of water. As the water-soluble substances dissolve, the stearic acid-modified magnesium citrate-lysine hydrochloride complex dissociates, the water-soluble substances dissolve, and the insoluble substances are dissolved in the surfactant. Under the action of, the insoluble substances are mainly a small amount of stearic acid and stearate, forming a uniform dispersion system in component B, which will only affect the transparency and clarity of the entire system, and will not affect the dissolution and absorption of branched-chain amino acids, nor will it have any effect on the body; during the dissociation process of the stearic acid-modified magnesium citrate-lysine hydrochloride complex, an ion solution enrichment will be formed in the pores of the betaine-branched-chain amino acid eutectic porous particles, increasing the osmotic pressure of water, further promoting the entry of water into the gaps of the porous particles, and water infiltrating into the gaps of the porous particles causes the porous particle structure to rupture and fully contact and dissolve with the fast-dissolving betaine-branched-chain amino acid eutectic particles, thereby achieving the effects of low hydrophilicity, moisture absorption, and fast dissolution in the solvent under storage environment (including natural environment containing air and moisture).

[0007] The stearic acid-modified magnesium citrate-lysine hydrochloride complex in the present application is filled in the betaine-branched-chain amino acid eutectic porous particles, but the betaine-branched-chain amino acid eutectic porous particles are not hermetically wrapped and completely waterproofed; the present application only ensures that the branched-chain amino acid composition will not absorb moisture and deteriorate for a longer period of time than the prior art when exposed to an environment with a humidity between 60-80%.

[0008] After the betaine-branched-chain amino acid eutectic porous particles are wrapped by the aqueous phase in the hypertonic component B, they will also partially dissolve themselves. With the reduction of the interfacial tension of the stearic acid-modified magnesium citrate-lysine hydrochloride complex in component B and the local enrichment of the ionic solution, not only the disintegration of the stearic acid-modified magnesium citrate-lysine hydrochloride complex is achieved, but also the permeability of the aqueous phase in the betaine-branched-chain amino acid eutectic porous particles is enhanced and the dissolution rate of the betaine-branched-chain amino acid eutectic porous particles is further increased. Therefore, the present application realizes that the branched-chain amino acid composition can be quickly dissolved and can have a longer storage time than the prior art in a natural environment, reducing the sealing requirements for sealed storage.

[0009] The stearic acid hydrophobic layer is generally dense. Therefore, in order to ensure that the hydrophobic layer can disintegrate during dissolution, the present application uses a stearic acid modified magnesium citrate-lysine hydrochloride complex, a hydrophobic-hydrophilic modified complex, to replace the stearic acid hydrophobic layer. The hydrophobic-hydrophilic modified complex, under the action of a surfactant, utilizes the dissolution of the hydrophilic layer to achieve the disintegration of the hydrophobic layer.

[0010] Furthermore, the betaine-branched-chain amino acid eutectic porous particles are obtained by the following method: a betaine-branched-chain amino acid eutectic complex with a mass ratio of 1:1 is subjected to an anti-solvent method to obtain a betaine-branched-chain amino acid eutectic slurry, and the eutectic slurry is subjected to three-stage drying and then fluidized treatment to obtain betaine-branched-chain amino acid eutectic porous particles.

[0011] Furthermore, the branched-chain amino acid complex includes leucine, isoleucine, and valine.

[0012] Furthermore, the mass ratio of leucine, isoleucine and valine is 2:1:1.

[0013] Furthermore, the component B comprises the following components, based on the total weight of the component B: 85-89 wt % of water, 8-10 wt % of mannitol, and 3-5 wt % of an amphiphilic surfactant.

[0014] Furthermore, the addition ratio of component A to component B is 5-7.5:200 g / ml, and 200 ml of component B is required to dissolve every 5-7.5 g of component A.

[0015] Furthermore, the stearic acid-modified magnesium citrate-lysine hydrochloride complex is prepared by the following method: magnesium citrate and lysine hydrochloride are mixed in deionized water in a mass ratio of 1:1, stirred and heated for 2-4 hours, and then stearic acid and sodium lauryl sulfate are added to continue the reaction, followed by cooling, filtering, washing, drying, and crushing to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride complex; wherein the amount of stearic acid added is 20-30wt% of the total mass of magnesium citrate and lysine hydrochloride, and the amount of sodium lauryl sulfate added is 10-12wt% of the stearic acid.

[0016] Furthermore, the amphiphilic surfactant is a lecithin surfactant.

[0017] Furthermore, the three-stage drying of the eutectic slurry includes the following steps: First stage: 0.2 mbar vacuum, 8 hours, -30 ° C to -10 ° C; Level 2: -5℃ constant temperature for 2h; The third stage: 12h, temperature rise from -5℃ to 25℃.

[0018] The branched-chain amino acid composition for supplying energy to skeletal muscle is used to prepare a nutrient for supplying energy to skeletal muscle.

[0019] In summary, due to the adoption of the above technical solution, the beneficial effects of the present invention are: 1. The present invention provides a branched-chain amino acid composition for skeletal muscle energy supply. The composition prepares betaine-branched-chain amino acid eutectic porous particles to improve the water solubility of the branched-chain amino acids and ensure the basic instant solubility of the branched-chain amino acids. On this basis, a stearic acid-modified magnesium citrate-lysine hydrochloride complex is added. The stearic acid-modified magnesium citrate-lysine hydrochloride complex is filled in the pores of the betaine-branched-chain amino acid eutectic porous particles. The porous particles are hydrophobically modified to reduce the hydrophilicity and hygroscopicity of the porous particles during storage, thereby solving the problem of moisture absorption during storage. 2. To balance the two properties of rapid solubility in solvents and hydrophobicity and moisture resistance under storage conditions, the present invention is configured with component B. Component B uses water as the main solubilizer and is added with mannitol and an amphiphilic surfactant. Component B can disintegrate the stearic acid-modified magnesium citrate-lysine hydrochloride complex, destroying hydrophobic sites and exposing solubility points, ensuring rapid dissolution of the branched-chain amino acids. 3. The betaine-branched-chain amino acid cocrystal of the present invention is a porous particle. The porous structure can not only accommodate the stearic acid-modified magnesium citrate-lysine hydrochloride complex, but also help to increase the dissolution rate of the branched-chain amino acids. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and should not be considered as limiting the scope. A person of ordinary skill in the art can also derive other relevant drawings based on these drawings without inventive effort, among which: Figure 1 This is a physical picture of component A; Figure 2 This is a microscopic image of the particle surface of component A. DETAILED DESCRIPTION

[0021] In order to make the objectives, technical solutions, and advantages of the present invention more clearly understood, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only intended to explain the present invention and are not intended to limit the present invention. That is, the embodiments described herein are only some embodiments of the present invention, not all embodiments. Generally, the components of the embodiments of the present invention described and illustrated in the drawings herein may be arranged and designed in various different configurations.

[0022] Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the invention as claimed, but is merely intended to represent selected embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative work are within the scope of protection of the present invention.

[0023] It should be noted that relational terms such as "first" and "second" are used only to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the terms "comprises," "comprising," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus comprising a series of elements includes not only those elements, but also other elements not explicitly listed, or elements inherent to such process, method, article, or apparatus. In the absence of further limitations, an element defined by the phrase "comprising a ..." does not exclude the presence of additional identical elements in the process, method, article, or apparatus comprising the element.

[0024] The features and performance of the present invention are further described in detail below with reference to the embodiments.

[0025] An embodiment of the present invention provides a branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; component B is a solution of component A; The component A comprises the following components: a stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched-chain amino acid eutectic porous particles; the amount of the stearic acid-modified magnesium citrate-lysine hydrochloride complex added accounts for 12-15% of the mass of the betaine-branched-chain amino acid eutectic porous particles; the particle size range of the stearic acid-modified magnesium citrate-lysine hydrochloride complex particles is within the pore size range of the betaine-branched-chain amino acid eutectic porous particles; the stearic acid-modified magnesium citrate-lysine hydrochloride complex can fill into the pores of the betaine-branched-chain amino acid eutectic porous particles; and the lysine hydrochloride is L-lysine hydrochloride.

[0026] The component B comprises the following components: water, mannitol, and an amphiphilic surfactant.

[0027] The betaine-branched-chain amino acid eutectic porous particles are obtained by the following method: a betaine-branched-chain amino acid eutectic complex having a mass ratio of 1:1 is subjected to an anti-solvent method to obtain a betaine-branched-chain amino acid eutectic slurry, and the eutectic slurry is subjected to a three-stage drying and then fluidized treatment to obtain the betaine-branched-chain amino acid eutectic porous particles; the three-stage drying comprises the following steps: First stage: 0.2 mbar vacuum, 8 hours, -30 ° C to -10 ° C; Level 2: -5℃ constant temperature for 2h; The third stage: 12h, temperature rise from -5℃ to 25℃.

[0028] The branched-chain amino acid complex comprises leucine, isoleucine and valine, and the mass ratio of the leucine, isoleucine and valine is 2:1:1.

[0029] The component B comprises the following components, based on the total weight of the component B: 85-89 wt % of water, 8-10 wt % of mannitol, and 3-5 wt % of an amphiphilic surfactant.

[0030] The addition ratio of component A to component B is 5-7.5:200 g / ml, and 200 ml of component B is required to dissolve every 5-7.5 g of component A.

[0031] The stearic acid-modified magnesium citrate-lysine hydrochloride complex is prepared by the following method: magnesium citrate and lysine hydrochloride are mixed in deionized water at a mass ratio of 1:1, stirred and heated for 2-4 hours, and then stearic acid and sodium lauryl sulfate are added to continue the reaction. The mixture is then cooled, filtered, washed, dried, and crushed to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride complex. The amount of stearic acid added is 20-30 wt % of the total mass of the magnesium citrate and lysine hydrochloride, and the amount of sodium lauryl sulfate added is 10-12 wt % of the stearic acid. The sodium lauryl sulfate is food grade.

[0032] The amphiphilic surfactant is a lecithin surfactant.

[0033] The branched-chain amino acid composition for supplying energy to skeletal muscle is used to prepare a nutrient for supplying energy to skeletal muscle.

[0034] Examples 1-9: Based on the above content, Examples 1 to 9 respectively provide a branched-chain amino acid composition for skeletal muscle energy supply, the difference being that the component ratios of component A and component B are different, and the amount of stearic acid added to the stearic acid-modified magnesium citrate-lysine hydrochloride complex is different. The preparation methods are the same, and the differences are shown in Table 1.

[0035] Examples 1 to 9 provide a branched-chain amino acid composition for skeletal muscle energy supply, comprising component A and component B; component B is a dissolving solution of component A; the addition ratio of component A to component B is 5:200 g / ml, and 200 ml of component B is required to dissolve 5 g of component A; The component A comprises the following components: a stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched-chain amino acid eutectic porous particles; the particle size range of the stearic acid-modified magnesium citrate-lysine hydrochloride complex particles is within the pore size range of the betaine-branched-chain amino acid eutectic porous particles; the stearic acid-modified magnesium citrate-lysine hydrochloride complex can fill into the pores of the betaine-branched-chain amino acid eutectic porous particles; The component B comprises the following components: water, mannitol, and an amphiphilic surfactant; the branched-chain amino acid complex comprises leucine, isoleucine, and valine, and the mass ratio of leucine, isoleucine, and valine is 2:1:1; and the amphiphilic surfactant is a lecithin surfactant; A method for preparing a branched-chain amino acid composition for skeletal muscle energy supply comprises the following steps: S1. Prepare component A: dry-mix 30% of the total amount of the stearic acid-modified magnesium citrate-lysine hydrochloride complex with betaine-branched-chain amino acid eutectic porous particles to obtain a premix; then disperse the remaining stearic acid-modified magnesium citrate-lysine hydrochloride complex in anhydrous ethanol containing 10% by mass of food-grade sodium lauryl sulfate (anhydrous ethanol is the total amount measured) to obtain a stearic acid-modified magnesium citrate-lysine hydrochloride complex suspension; place the premix in a fluidized bed, introduce 37° C. hot air for fluidization, and simultaneously spray-inject the stearic acid-modified magnesium citrate-lysine hydrochloride complex suspension, and finally dry to obtain component A, which is sealed and stored; S2. Prepare Component B: Dissolve mannitol in 50°C deionized water and stir until completely dissolved. Cool to 30°C, add an amphiphilic surfactant, and homogenize to obtain Component B. Seal and store. Components A and B are packaged separately according to the usage ratio. Components B and A are typically packaged in separate bags, but Component A can also be packaged in large-capacity cans.

[0036] The physical picture of component A prepared within the scope of Example 6 is as follows Figure 1 As shown, the particles are uniform and have no visible impurities. The SEM image of the particle surface is as follows Figure 2 As shown, there are obvious pores and fillings.

[0037] Table 1 Example 1-Implementation 9 composition ratio: .

[0038] Embodiment 10, 11: Examples 10-11 respectively provide a branched-chain amino acid composition for supplying energy to skeletal muscle. The difference from Example 6 is that the addition ratio of component A and component B is different. The differences are shown in Table 2.

[0039] Table 2 The addition ratio of component A and component B in Example 6 and Examples 10-11: .

[0040] Comparative Example 1: Based on Example 6, this comparative example differs from Example 6 in that component B is not included, and the dissolving liquid of component A is deionized water.

[0041] Comparative Example 2: Based on Example 6, this comparative example is different from Example 6 in that component B does not include mannitol.

[0042] Comparative Example 3: Based on Example 6, this comparative example is different from Example 6 in that component B does not include an amphiphilic surfactant.

[0043] Comparative Example 4: Based on Example 6, this comparative example differs from Example 6 in that: the component A includes the following components: a stearic acid-modified calcium carbonate complex and betaine-branched-chain amino acid eutectic porous particles.

[0044] Comparative Example 5: Based on Example 6, this comparative example differs from Example 6 in that: the component A includes the following components: a magnesium citrate-lysine hydrochloride complex (not modified with stearic acid) and betaine-branched-chain amino acid eutectic porous particles.

[0045] Comparative Example 6: Based on Example 6, this comparative example differs from Example 6 in that the component A does not include the stearic acid-modified magnesium citrate-lysine hydrochloride complex.

[0046] Comparative Example 7: Based on Example 6, this comparative example differs from Example 6 in that: the component A includes stearic acid and betaine-branched-chain amino acid eutectic porous particles.

[0047] Comparative Example 8: Based on Example 6, this comparative example differs from Example 6 in that: the component A includes a stearic acid-modified magnesium citrate-lysine hydrochloride complex and branched-chain amino acid porous particles (excluding betaine).

[0048] Comparative Example 9: Based on Example 6, this comparative example is different from Example 6 in that: the component A does not include lysine hydrochloride.

[0049] Comparative Example 10: Based on Example 6, this comparative example is different from Example 6 in that component A does not include magnesium citrate.

[0050] Comparative Example 11: Based on Example 6, this comparative example is different from Example 6 in that: the betaine-branched-chain amino acid eutectic porous particles are obtained by the following method: a betaine and branched-chain amino acid complex with a mass ratio of 1:1 is subjected to an anti-solvent method to obtain a betaine-branched-chain amino acid eutectic slurry, and the eutectic slurry is dried and then fluidized to obtain betaine-branched-chain amino acid eutectic porous particles; drying does not include the first stage: under a vacuum of 0.2 mbar, for 8 hours, heating from -30°C to -10°C.

[0051] Comparative Example 12: Based on Example 6, the difference between this comparative example and Example 6 is that in the preparation method of the betaine-branched-chain amino acid eutectic porous particles, the drying treatment does not include the second stage: constant temperature at -5°C for 2h.

[0052] Test Example 1: The dissolution time of component A and component B in Examples 1-11 and Comparative Examples 1-12, after mixing in corresponding proportions under stirring, and the macroscopic characteristics of the dissolved solution after dissolution were respectively tested. The detection method is the existing technology. The results are shown in Table 3.

[0053] The branched-chain amino acid composition in the present application will not be completely dissolved, and a small amount of substances insoluble in the aqueous phase will form a uniform and stably dispersed dispersion system. Therefore, the dissolution described throughout the present application does not mean that all substances are completely dissolved and present a completely clear state, but rather a milky white and translucent uniform dispersion system with no visible precipitates.

[0054] Mix components A and B according to their ratio and record the dissolution time of component A in component B under magnetic stirring (200 rpm) until the solution becomes uniform, milky white and translucent with no visible particles. This is the macroscopic characterization of the solution.

[0055] Table 3 Dissolution time of branched-chain amino acid composition and macroscopic characteristics of the dissolved solution: .

[0056] Key parameters affecting dissolution time include the proportion of stearic acid-modified magnesium citrate-lysine hydrochloride complex, the proportion of stearic acid, the content of amphiphilic surfactants, and the content of mannitol. This application coordinates the values ​​of these factors to achieve optimal synergy, resulting in a dissolution rate superior to existing technologies. For existing fast-dissolving branched-chain amino acids, reference can be made to patents such as 202211617864.9. Although the dissolving solution of the present invention is not clear, the dissolution time is superior to that of the prior art. Without affecting the dissolution of the branched-chain amino acids, it can be understood that the dissolving solution in this application differs only in physical characteristics and does not affect the normal absorption of the branched-chain amino acids.

[0057] Test Example 2: The hygroscopicity of component A in Examples 1-3 and Comparative Examples 4-12 was tested. 5 g of component A was placed in a constant humidity chamber at 60%, 70%, and 80% humidity and a temperature of 25°C. The moisture absorption rate was recorded daily. A moisture absorption rate greater than 5% was considered failure, and the time to failure was recorded in days. The results are shown in Table 4. The control group was the mixed instant branched-chain amino acid prepared in Example 5 of patent CN202211617864.9.

[0058] Table 4 Hygroscopicity of component A: .

[0059] The factors affecting the hygroscopicity of component A mainly include the addition ratio of the stearic acid-modified magnesium citrate-lysine hydrochloride complex in component A, the addition ratio of stearic acid in the complex, the eutectic structure, and the filling effect between the eutectic structure and the complex. The addition ratio of the stearic acid-modified magnesium citrate-lysine hydrochloride complex in component A and the addition ratio of stearic acid in the complex do not mean that the higher the hydrophobicity, the better. It is necessary to comprehensively consider the hydrophobic properties of the complex itself (influenced by the proportion of stearic acid) and the pore filling effect between it and the porous particles (mainly affected by the proportion of the stearic acid-modified magnesium citrate-lysine hydrochloride complex); Therefore, the data in Tables 3 and 4 of this application show that Example 6 can be used as a better solution. The data in Table 4 of this application >3.5-4 means greater than 3.5 and less than or equal to 4. As a reference, the expression of other data is also consistent; >3.5-4 (excluding 4) means greater than 3.5 and less than 4.

[0060] Test Example 3: The content of branched-chain amino acids in the solid matter obtained by centrifuging the solid-liquid separation of the homogeneous liquid obtained by mixing component A and component B in Example 1-11 was detected. The results are shown in Table 5.

[0061] Table 5 Branched-chain amino acid content in the solid after solid-liquid separation: .

[0062] Test Example 4: Microbial detection and toxicity tests were performed on the homogeneous liquid obtained by mixing component A and component B in Examples 1-11. No Cronobacter, Staphylococcus aureus, Salmonella, or Escherichia coli were detected. The product passed the acute oral toxicity test according to GB 15193.3-2014 national food safety standard and was non-toxic.

[0063] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions and improvements made by any technician familiar with the field within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A branched-chain amino acid composition for skeletal muscle energy supply, characterized in that: It comprises component A and component B; component B is a dissolving liquid of component A; The component A comprises the following components: a stearic acid-modified magnesium citrate-lysine hydrochloride complex and betaine-branched chain amino acid eutectic porous particles; the amount of the stearic acid-modified magnesium citrate-lysine hydrochloride complex added accounts for 12-15% of the mass of the betaine-branched chain amino acid eutectic porous particles; The component B comprises the following components: water, mannitol, and an amphiphilic surfactant.

2. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The betaine-branched-chain amino acid eutectic porous particles are obtained by the following method: a betaine and branched-chain amino acid complex with a mass ratio of 1:1 is subjected to an anti-solvent method to obtain a betaine-branched-chain amino acid eutectic slurry; the eutectic slurry is subjected to three-stage drying and then fluidized treatment to obtain the betaine-branched-chain amino acid eutectic porous particles.

3. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 2, characterized in that: The branched-chain amino acid complex comprises leucine, isoleucine and valine.

4. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 3, characterized in that: The mass ratio of leucine, isoleucine and valine is 2:1:

1.

5. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The component B comprises the following components, based on the total weight of the component B: 85-89 wt % of water, 8-10 wt % of mannitol, and 3-5 wt % of an amphiphilic surfactant.

6. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The addition ratio of component A to component B is 5-7.5:200 g / ml, and 200 ml of component B is required to dissolve every 5-7.5 g of component A.

7. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The stearic acid-modified magnesium citrate-lysine hydrochloride complex is prepared by the following method: magnesium citrate and lysine hydrochloride are mixed in deionized water at a mass ratio of 1:1, stirred and heated for reaction for 2-4 hours, and then stearic acid and sodium lauryl sulfate are added to continue the reaction, followed by cooling, filtering, washing, drying, and pulverizing to obtain the stearic acid-modified magnesium citrate-lysine hydrochloride complex; wherein the amount of stearic acid added is 20-30wt% of the total mass of the magnesium citrate and lysine hydrochloride, and the amount of sodium lauryl sulfate added is 10-12wt% of the stearic acid.

8. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 1, characterized in that: The amphiphilic surfactant is a lecithin surfactant.

9. The branched-chain amino acid composition for skeletal muscle energy supply according to claim 2, characterized in that: Three-stage drying The following steps are involved: First stage: 0.2 mbar vacuum, 8 hours, -30 ° C to -10 ° C; Level 2: -5℃ constant temperature for 2h; The third stage: 12h, temperature rise from -5℃ to 25℃.

10. The branched-chain amino acid composition for skeletal muscle energy supply according to any one of claims 1 to 9, characterized in that: Nutrients used to prepare skeletal muscle energy.

Images